6th International Immunoglobulin Symposium: Poster presentations

Clinical and Experimental Immunology

Volumn 158, Issue SUPPL. 1, 2009, Pages 60-67

  Fernandez Cruz, E ^a   Kaveri, S V ^b   Peter, H H ^c   Durandy, A ^d   Cantoni, N ^e   Quinti, I ^f   Sorensen, R ^g   Bussel, J B ^h   Danieli, M G ⁱ   Winkelmann, A ^j   Bayry, J ^b   Kasermann F ^k   Spath P ^l   Helbert, M ^m   Salama, A ⁿ   Van Schaik, I N ^o   Yuki, N ^p  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

^c UNIVERSITY OF FREIBURG   (Germany)

^d INSERM   (France)

^e UNIVERSITY HOSPITAL BASEL   (Switzerland)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

^g CHILDREN S HOSPITAL   (United States)

^h WEILL CORNELL MEDICAL COLLEGE   (United States)

ⁱ UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^j UNIVERSITY OF ROSTOCK   (Germany)

^k CSL Behring AG   (Switzerland)

^l UNIVERSITY OF BERN   (Switzerland)

^m MANCHESTER ROYAL INFIRMARY   (United Kingdom)

ⁿ CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^o UNIVERSITY OF AMSTERDAM   (Netherlands)

^p National Hospital Organization Niigata National Hospital   (Japan)

more..

Author keywords

Antibody; Autoimmunity; Immunodeficiencies; Intravenous immunoglobulin; Subcutaneous immunoglobulin

Indexed keywords

CYCLOSPORIN A; IMMUNOGLOBULIN; IMMUNOGLOBULIN D; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ACUTE OTITIS MEDIA; ADD ON THERAPY; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNITY; BASIC RESEARCH; BRAIN HEMORRHAGE; CLINICAL RESEARCH; CLINICAL TRIAL; COMMON VARIABLE IMMUNODEFICIENCY; CREUTZFELDT JAKOB DISEASE; DENDRITIC CELL; DERMATOMYOSITIS; DRUG DOSE TITRATION; DRUG MECHANISM; DRUG WITHDRAWAL; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; MEMORY CELL; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; MYOSITIS; NEONATAL ALLOIMMUNE THROMBOCYTOPENIA; PATIENT CARE; PNEUMONIA; POLYMYOSITIS; PRIORITY JOURNAL; RELAPSE; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; UNSPECIFIED SIDE EFFECT; X LINKED AGAMMAGLOBULINEMIA;

AUTOIMMUNE DISEASES; AUTOIMMUNITY; BIOMEDICAL RESEARCH; HUMANS; IMMUNOGLOBULINS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC DEFICIENCY SYNDROMES;

EID: 72149134629     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2009.04028.x     Document Type: Review

References (20)

1. Ballow M. Safety of IGIV therapy and infusion-related adverse events. Immunol Res 2007 38 : 122 132.
2. Durandy A, Wahn V, Petteway S et al. Immunoglobulin replacement therapy in primary antibody deficiency diseases - maximizing success. Int Arch Allergy Immunol 2005 136 : 217 229.
3. Péron S, Metin A, Gardès P et al. Human PMS2 deficiency is associated with impaired immunoglobulin class switch recombination. J Exp Med 2008 205 : 2465 2472.
4. Imai K, Slupphaug G, Lee WI et al. Human uracil-DNA glycosylase deficiency associated with profoundly impaired immunoglobulin class-switch recombination. Nat Immunol 2003 4 : 1023 1028.
5. Kadyrov FA, Dzantiev L, Constantin N et al. Endonucleolytic function of MutLalpha in human mismatch repair. Cell 2006 126 : 297 308.
6. Nydegger UE, Sturzenegger M. Adverse effects of intravenous immunoglobulin therapy. Drug Saf 1999 21 : 171 185.
7. Barandun S, Kistler P, Jeunet F et al. Intravenous administration of human g-globulin. Vox Sang 1962 7 : 157 164.
8. Bonilla FA. Intravenous immunoglobulin: adverse reactions and management. J Allergy Clin Immunol 2008 122 : 1238 1239.
9. Berger M. Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency. Immunol Allergy Clin North Am 2008 28 : 413 437, x.
10. Looney RJ, Huggins J. Use of intravenous immunoglobulin G (IVIG). Best Pract Res Clin Haematol 2006 19 : 3 25.
11. Arnold DM, Smith JW, Kelton JG. Diagnosis and management of neonatal alloimmune thrombocytopenia. Transfus Med Rev 2008 22 : 255 267.
12. Berkowitz RL, Bussel JB, McFarland JG. Alloimmune thrombocytopenia: state of the art 2006. Am J Obstet Gynecol 2006 195 : 907 913.
13. Berkowitz RL, Kolb EA, McFarland JG et al. Parallel randomized trials of risk-based therapy for fetal alloimmune thrombocytopenia. Obstet Gynecol 2006 107 : 91 6.
14. Dalakas MC, Illa I, Dambrosia JM et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993 329 : 1993 2000.
15. Danieli MG, Calcabrini L, Marchetti A et al. Intravenous immunoglobulin treatment in autoimmune diseases. Recenti Prog Med 2007 98 : 322 326 in Italian IN et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Eur J Neurol 2006 13 : 802 808.
16. Confavreux C, Hutchinson M, Hours MM et al. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med 1998 339 : 285 291.
17. Vukusic S, Hutchinson M, Hours M et al. Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain 2004 127 : 1353 1360.
18. Bayry J, Bansal K, Kazatchkine MD, Kaveri SV. DC-SIGN and alpha2,6-sialylated IgG Fc interaction is dispensable for the anti-inflammatory activity of IVIg on human dendritic cells. Proc Natl Acad Sci 2009 106 : E24.
19. Turner ML, Ludlam CA. An update on the assessment and management of the risk of transmission of variant Creutzfeldt-Jakob disease by blood and plasma products. Br J Haematol 2009 144 : 14 23.
20. Bayry J, Lacroix-Desmazes S, Carbonneil C et al. Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood 2003 101 : 758 765.